Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797973 | 1.00 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL241741 | 1.00 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14461324 | 0.92 | BACE1 (0.43) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL26964687 | 0.91 | BACE1 (0.36) | BACE1 | |
| SCHEMBL26964605 | 0.91 | BACE1 (0.36) | BACE1 | |
| SCHEMBL7344545 | 0.91 | BACE1 (0.36) | BACE1 | |
| SCHEMBL7344125 | 0.91 | BACE1 (0.36) | BACE1 | |
| SCHEMBL7339050 | 0.91 | BACE1 (0.36) | BACE1 | |
| SCHEMBL19984341 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL22283784 | 0.85 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017188288-A1 | 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATION ACTION | 塩野義製薬株式会社 | 2017-11-02 | — | — | WO | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-7417032-B2 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-26 | — | — | US | disclosed |
| EP-1773800-A1 | D-GLUCOPYRANOSYL PHENYL-SUBSTITUTED CYCLENE, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006018150-A1 | D-XYLOPYRANOSYL-PHENYL-SUBSTITUITED CYCLENE, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035841-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| WO-2006010557-A1 | D-GLUCOPYRANOSYL PHENYL-SUBSTITUTED CYCLENE, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| US-6013807-A | Antitumor tetracyclic compounds | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-01-11 | — | — | US | disclosed |
| US-5852204-A | Pyrrolo 3,2-b-!-carbazoles and 1H 1!benzothieno 2,3-f! indoles having anti-tumor activity | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 1998-12-22 | — | — | US | disclosed |
| EP-0741729-A1 | ANTITUMOUR TETRACYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995021170-A1 | ANTITUMOUR TETRACYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | BACE1 1435/4885CYP3A4 693/4885HTT 4627/4885 |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | BACE1 3421/4885CYP3A4 2599/4885HTT 3990/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | BACE1 3421/4885CYP3A4 2599/4885HTT 3990/4885 |
| US-20060035841-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | BACE1 1999/4885CYP3A4 469/4885HTT 3226/4885 |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | BACE1 1968/4885CYP3A4 404/4885HTT 3166/4885 |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | BACE1 1435/4885CYP3A4 693/4885HTT 4627/4885 |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | ACSS2, ACACB, ADCY2 | BACE1 1993/4885CYP3A4 548/4885HTT 4159/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | BACE1 3421/4885CYP3A4 2599/4885HTT 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.